Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATO: Continued Enzalutamide in mCRPC
NCT01995513Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Enzalutamide + Abiraterone with Placebo + Abiraterone (2 arms). Primary endpoint: Progression Free Survival up to 20.3 months. Started Oct 2013; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01995513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995513.